Topics:

From Chaos to Consilience: Part IIWhat the New Mind-Body Science Tells Us About the Pathophysiology of Major Depression: Page 3 of 3

From Chaos to Consilience: Part IIWhat the New Mind-Body Science Tells Us About the Pathophysiology of Major Depression: Page 3 of 3

Why is depression a risk factor for other diseases and why is it progressive?
While these seem like separate questions, the new mind-body science suggests that they are actually variations on a theme. Depression, in our view, is linked to most other modern illnesses because it shares an underlying pathophysiology with them.18,28 Millions of years of evolution favored the development and retention of extremely robust stress and inflammatory danger pathways. When death and destruction lurked around every corner, the safest policy was to fire off one’s danger pathways first and ask questions later. What did it matter if body and brain tissues were damaged a little each time these pathways activated if this kept one alive for today (an idea that has been popularized as allostatic load).29 No need to worry about heart disease, cancer, or dementia if you were likely to die of infection by age 30.

Consider our plight today, however. The boss no longer rips your arm off when he shouts at you, and many of the jobs once done by inflammation have been farmed out to sanitation and modern medicine. But the old danger pathways just go on firing off every time someone looks at us sideways. The more they fire off, the more damage accumulates. When this occurs in the arteries, it is vascular disease30; when it promotes insulin resistance, it is diabetes30; and when it disrupts glial cell integrity and disorganizes neuronal signaling, it manifests as depression.31,32 Given enough time, the damage usually accumulates everywhere—hence the high comorbidity between depression and most other major modern maladies.

Why is remission so important?
The new mind-body science suggests that depressive symptoms are a “shout out” that the brain and body are in a state that is inimical to optimal functioning and health in the modern world. Conversely, an implication of the ideas presented here is that depressive symptoms are not likely to improve unless a person’s underlying danger pathway functioning normalizes, at least to some degree.28,33 So remission is the best indicator we currently have that a person’s underlying physiology has returned to a safer state. Of course, symptoms are not perfect. If they were, remission would heal all ills.34 In fact, we know that even when remission is achieved, patients remain at greatly increased risk for sinking again into depression when compared with those who have never suffered depression.35

Join us next month as we apply the implications of recent scientific advances to the practicalities of diagnosing and treating depression.

Pages

References

1. First MB. Changes in psychiatric diagnosis. Psychiatr Times. 2008;25(13):14-16.
2. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med. 1999;341:1329-1335.
3. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of major depression. Trends Immunol. 2006;27:24-31.
4. McEwen BS. Mood disorders and allostatic load.
Biol Psychiatry. 2003;54:200-207.
5. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998;105:83-107.
6. Chen CH, Ridler K, Suckling J, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62:407-414.
7. Siegle GJ, Carter CS, Thase ME. Use of FMRI to predict recovery from unipolar depression with cognitive behavior therapy. Am J Psychiatry. 2006;163:735-738.
8. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008;29:683-695.
9. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-186.
10. Pace TW, Mletzko TC, Alagbe O, et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163:1630-1633.
11. Epstein J, Pan H, Kocsis JH, et al. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry. 2006;163: 1784-1790.
12. Siegle GJ, Thompson W, Carter CS, et al. Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry. 2007;61:198-209.
13. Dantzer R, O’Connor JC, Freund GG, et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.
14. Raison CL, Demetrashvili M, Capuron L, Miller AH. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs. 2005;19: 105-123.
15. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652.
16. Mayberg HS. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009;119:717-725.
17. Bares M, Kopecek M, Novak T, et al. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. J Affect Disord. 2009 Feb 25. [Epub ahead of print.]
18. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732-741.
19. Su S, Miller AH, Snieder H, et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom Med. 2009;71:152-158.
20. Schule C, Zill P, Baghai TC, et al. Brain-derived neurotrophic factor Val66Met polymorphism and dexa­methasone/CRH test results in depressed patients. Psychoneuroendocrinology. 2006;31:1019-1025.
21. Kendler KS, Kuhn JW, Vittum J, et al. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry. 2005; 62:529-535.
22. Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301:386-389.
23. Pauli-Pott U, Friedl S, Hinney A, Hebebrand J. Serotonin transporter gene polymorphism (5-HTTLPR), environmental conditions, and developing negative emotionality and fear in early childhood. J Neu­ral Transm. 2009;116:503-512.
24. Jamison KR. Touched With Fire: Manic-Depressive Illness and the Artistic Temperament. New York: Free Press; 1993.
25. Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry. 2008 May 6. [Epub ahead of print.]
26. Kraus MR, Al-Taie O, Schafer A, et al. Serotonin-1A receptor gene HTR1A variation predicts inter­feron-induced depression in chronic hepatitis C. Gastro­enterology. 2007;132:1279-1286.
27. Gentile DA, Doyle WJ, Zeevi A, et al. Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol. 2003;64:338-344.
28. Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci. 2009;14:5291-5338.
29. McEwen BS. Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci. 2004;1032:1-7.
30. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65
(12, pt 2):S253-S259.
31. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr. 2008;13:501-510.
32. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219-233.
33. Ising M, Horstmann S, Kloiber S, et al. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression—
a potential biomarker? Biol Psychiatry. 2007;62:47-54.
34. Aubry JM, Gervasoni N, Osiek C, et al. The DEX/CRH neuroendocrine test and the prediction of depressive relapse in remitted depressed outpatients. J Psychiatr Res. 2007;41:290-294.
35. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.